JPRN-jRCT2021220007招募中3 期
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
Ahmadur Rahman, M.B.B.S.0 个研究点目标入组 320 人开始时间: 2022年5月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •*Inclusion Criteria (All Cohorts):
- •- Body weight >/= 30 kg at screening
- •- Willingness and ability to use the electronic device(s) or application(s) for the electronic patient-reported outcome (PRO)
- •- Whole-body positron emission tomography/computed tomography scan (PET/CT) (from the base of skull to mid-thighs) for the purposes of staging, performed prior and within 42 days of the first dose of cCRT or sCRT
- •- Histologically or cytologically documented locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology
- •- Prior receipt of at least two prior cycles of platinum-based chemotherapy given concurrently with radiotherapy (cCRT); or at least two prior cycles of platinum-based chemotherapy given prior to radiotherapy (sCRT)
- •- The RT component in the cCRT or sCRT must have been at a total dose of radiation of 60 (+/-10%) Gy (54 Gy to 66 Gy) administered by intensity-modulated radiotherapy (preferred) or three dimension (3D)-conforming technique
- •- No disease progression during or following platinum-based cCRT or sCRT
- •- Life expectancy >/= 12 weeks
- •- Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen
- •- Documented tumor PD-L1 status (TC score < 1% vs. >/= 1% vs. unknown) as determined: centrally with the SP263 IHC assay on the confirmed available FFPE tumor specimen; locally, with the SP263 (preferred) or 22C3 IHC assays
- •- Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2
- •- Adequate hematologic and end-organ function
- •- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, as defined by the protocol
- •- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm, as defined by the protocol
- •*Inclusion criteria specific to Cohort A1:
- •- Documented ALK fusion positivity by an eligible result from: centralized multiplex molecular testing of tumor tissue at the Sponsor's designated central laboratory under Study BX43361 or available results from a Sponsor pre-approved local, appropriately validated ALK fusion test on tumor tissue performed in a Clinical Laboratory Improvement Amendments certified or equivalent laboratory
- •*Inclusion criteria specific to Cohort A2:
- •- Documented ROS1 fusion positivity by an eligible result from: centralized multiplex molecular testing of tumor tissue at the Sponsor's designated central laboratory under Study BX43361 or available results from a Sponsor pre-approved local, appropriately validated ROS1 fusion test on tumor tissue performed in a Clinical Laboratory Improvement Amendments certified or equivalent laboratory
- •- Ability to swallow entrectinib intact, without chewing, crushing, or opening the capsules
- •*Inclusion criteria specific to Cohort A3:
- •- Documented RET fusion positivity by an eligible result from: centralized multiplex molecular testing of tumor tissue at the Sponsor's designated central laboratory under Study BX43361 or available results from a Sponsor pre-approved local, appropriately validated RET fusion test on tumor tissue performed in a Clinical Laboratory Improvement Amendments certified or equivalent laboratory
排除标准
- •Only all Cohorts (Excerpt):
- •- Any history of previous NSCLC and/or any history of prior treatment for NSCLC (patients must be newly diagnosed with unresectable Stage III disease)
- •- Any evidence of Stage IV disease
- •- If a pleural effusion is present, the following criteria must be met to exclude malignant involvement (T4 disease): when pleural fluid is visible on both the CT scan and chest X-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative; participants with exudative pleural effusions are excluded regardless of cytology; participants with effusions that are minimal (i.e., not visible on chest X-ray) that are too small to safely tap are eligible
- •- NSCLC known to have a known or likely oncogenic-driver mutation in the EGFR gene, as identified by site local testing or Sponsor central testing
- •- Liver disease, characterized by any of the following: impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease, such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices or active viral or active autoimmune, alcoholic, or other types of acute hepatitis
- •- Positive hepatitis B surface antigen (HBsAg) test at screening
- •- Participants known to be positive for hepatitis C virus (HCV) antibody (Ab) are excluded with the following exception: participants who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible
- •- HIV infection: participants are excluded if not well-controlled as defined by the protocol
- •- Known active tuberculosis
- •- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest CT scan
- •- Grade >/= 2 pneumonitis from prior cCRT or sCRT
- •- Any Grade > 2 unresolved toxicity from prior cCRT or sCRT
- •- Any gastrointestinal disorder that may affect absorption of oral medications
- •- Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
- •- Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
- •- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated protein 4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
- •- Prior allogeneic stem cell or solid organ transplantation
- •- Any prior Grade >/= 3 immune-mediated adverse event or any unresolved Grade > 1 immune-mediated adverse event while receiving any previous immunotherapy agent other than immune checkpoint blockade agents
研究者
相似试验
招募中
1 期
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)on-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-503920-14-00F. Hoffmann-La Roche AG385
招募中
1 期
A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: blood-first assay screening trial)Advanced or metastatic Non-small cell lung cancer (NSCLC)CTIS2023-507500-31-00F. Hoffmann-La Roche AG616
已完成
2 期
A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)on-Small Cell Lung CancerJPRN-jRCT2080223780CHUGAI PHARMACEUTICAL CO., LTD.580
招募中
1 期
A Study to Find Out How Effective and Safe Different Treatments are in Patients Who Have a Type of Lung Cancer (Known as Non-Small Cell Lung Cancer [Stage III])on-Small Cell Lung Cancer (NSCLC)MedDRA version: 23.1Level: LLTClassification code 10084713Term: TumorSystem Organ Class: 100000004864EUCTR2021-004149-19-ITF. HOFFMANN - LA ROCHE LTD.320
尚未招募
不适用
A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCERNL-OMON53740Roche Nederland B.V.3